AU Patent

AU2013365926B9 — Novel heterocyclic compounds as bromodomain inhibitors

Assigned to Zenith Epigenetics Ltd · Expires 2019-01-17 · 7y expired

What this patent protects

The present disciosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

USPTO Abstract

The present disciosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: AU2013365926B9
Jurisdiction: AU
Classification: —
Expires: 2019-01-17
Drug substance claim: No
Drug product claim: No
Assignee: Zenith Epigenetics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.